DUBLIN--(BUSINESS WIRE)--The "SERNIVO Drug Profile, 2019" report has been added to ResearchAndMarkets.com's offering.
SERNIVO Drug Profile, 2019 is part of a deep library of business intelligence on biopharmaceutical drugs. The report focuses on SERNIVO and covers the following critical aspects of this drug:
- United States patents
- FDA Paragraph IV patent challenges
- District Court patent litigation
- Drug prices
- Annual sales revenues
- Finished product suppliers
- Raw active pharmaceutical ingredient (API) sources
Topics Covered
- Profile for SERNIVO
- US Patents
- US Regulatory Exclusivity
- Paragraph IV Patent Challenges
- US District Court Litigation
- International (ex US) Patents
- Drug Prices - Average Pharmacy Cost
- Drug Prices - Best Wholesale Price
- Annual Sales Revenues
- Finished Product Suppliers
- Bulk API Sources
Companies Featured
- Promius Pharma Llc
- Novoseek
- Tci (Tokyo Chemical Industry)
- Molport
- Abi Chem
- Timtec
- Chemmol
- Abblis Chemicals
- Akos Consulting & Solutions
- Chembase.Cn
- Key Organics/Bionet
- Wolves R&D Chemical
- An Pharmatech
- Race Chemical
- Targetmol
- Clearsynth
- Changzhou Highassay Chemical Co. Ltd
-
Acorn Pharmatech
- Phion Ltd
- Parchem
- Apexbio Technology
- Chem-Space.com Database
- LGC Standards
- Medchemexpress Mce
- Selleckchem
- Abachemscene
- Chemieliva Pharmaceutical Co. Ltd
- Ichemical Technology USA Inc
- Musechem
- Bld Pharm
For more information about this report visit https://www.researchandmarkets.com/research/wkkflg/sernivo_drug?w=4